TNFRSF17 and Miyoshi myopathy: Teclistamab is a T-cell-redirecting bsAb that targets both CD3 expressed on T cells and BCMA expressed on MM cells and it is the first bsAb drug approved by the European Medicines Agency in the RRMM setting, due to the promising results of the ongoing phase I/II MajesTEC-1 study (NCT04557098) [163].